Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin  by Holland, Carrie A et al.
E¡ect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition
by heparin cofactor II and antithrombin
Carrie A. Holland, Alexis T. Henry, Herbert C. Whinna, Frank C. Church*
Departments of Pathology and Laboratory Medicine, Pharmacology, and Medicine, and Center for Thrombosis and Hemostasis,
The University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, NC 27599-7035, USA
Received 4 September 2000; revised 29 September 2000; accepted 4 October 2000
First published online 17 October 2000
Edited by Pierre Jolles
Abstract ‘Thrombin aptamers’ are based on the 15-nucleotide
consensus sequence of d(GGTTGGTGTGGTTGG) that binds
specifically to thrombin’s anion-binding exosite-I. The effect of
aptamer^thrombin interactions during inhibition by the serine
protease inhibitor (serpin) heparin cofactor II (HCII) and
antithrombin (AT) has not been described. Thrombin inhibition
by HCII without glycosaminoglycan was decreased Vtwo-fold
by the aptamer. In contrast, the aptamer dramatically reduced
thrombin inhibition by s 200-fold and 30-fold for HCII^heparin
and HCII^dermatan sulfate, respectively. The aptamer had
essentially no effect on thrombin inhibition by AT with or without
heparin. These results add to our understanding of thrombin
aptamer activity for potential clinical application, and they
further demonstrate the importance of thrombin exosite-I during
inhibition by HCII^glycosaminoglycans. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
K-Thrombin is a trypsin-like serine protease involved in a
multitude of physiological processes [1,2]. Thrombin is the last
protease in the clotting cascade functioning to cleave soluble
¢brinogen to insoluble ¢brin that forms the ¢brin gel either of
a physiologic plug or a pathologic thrombus [1^4]. In addi-
tion, thrombin will potentiate the procoagulant process by
activating Factors V, VIII, XI and XIII. Conversely, follow-
ing its binding to thrombomodulin, thrombin aids the anti-
coagulant process by activating protein C [5,6]. Thrombin is
also involved with other activities including in£ammation and
wound healing [7^9].
Thrombin and other coagulation proteases are regulated in
vivo by a series of mechanisms including the protein C path-
way already mentioned, tissue factor pathway inhibitor com-
plex formation, and also a collection of plasma proteins in-
cluding antithrombin (AT) and heparin cofactor II (HCII)
[10^12]. AT and HCII are members of the serine protease
inhibitor (serpin) superfamily [13,14], and these inhibitors
form 1:1 complexes with thrombin that render thrombin pro-
teolytically inactive. Once formed the complexes are cleared
via the low-density lipoprotein receptor-related protein [15].
The rates of protease inhibition by these serpins are signi¢-
cantly increased in the presence of glycosaminoglycans such as
heparin/heparan sulfate for both AT and HCII and dermatan
sulfate for HCII.
A new class of thrombin inhibitors has recently been de-
scribed [16^19]. These inhibitors are based on sequence-spe-
ci¢c single-stranded DNA oligonucleotides, termed ‘thrombin
aptamers’. Bock and coworkers selected a pool of single-
stranded DNA oligonucleotides that were found to inhibit
thrombin’s ability to clot ¢brinogen at nM concentrations
[16^18]. The 15-nucleotide consensus sequence d(GGTTGG-
TGTGGTTGG) found in nearly all samples of thrombin ap-
tamer was found to display signi¢cant AT activity. The
thrombin aptamer works by binding to thrombin’s anion-
binding exosite-I, one of thrombin’s two highly basic regions
that form secondary binding sites on the surface of the mol-
ecule [20,21]. This basic region of thrombin contributes to the
macromolecular substrate speci¢city of thrombin with sub-
stances like ¢brinogen, hirudin, and HCII [22,23]. Thrombin
aptamers represent a new type of inhibitor with signi¢cant
antithrombotic and anticoagulant properties, and due to their
chemistry they may prove useful in various biomedical appli-
cations [16^19,24].
The goal of the project was to evaluate the in£uence of the
DNA aptamer^thrombin interaction during inhibition by the
serpins HCII and AT. The interactions were measured in both
the presence and absence of the glycosaminoglycans heparin
and dermatan sulfate. Based on these experiments, we have
further shown the importance of thrombin exosite-I in regu-
lating the HCII^thrombin inhibition reaction in the presence
of glycosaminoglycans.
2. Materials and methods
2.1. Proteins and reagents
Plasma derived human K-thrombin, QT-thrombin, HCII and AT
were prepared and puri¢ed to homogeneity as described previously
[25^27]. The thrombin aptamers were provided by Dr. Craig S. Gibbs
(Gilead Sciences, Foster City, CA, USA) and were: d(GGTTGGTG-
TGGTTGG) aptamer; and d(GGTGGTGGTTGTGGT) scrambled
aptamer. Unbleached crude heparin was obtained from Diosynth
(Oss, The Netherlands). Dermatan sulfate (Calbiochem) was treated
with nitrous acid to remove contaminating heparin/heparan sulfate as
detailed [28].
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2.2. Serpin/thrombin activity
Prior to performing the serpin^thrombin assays, it was necessary to
choose a bu¡er with the appropriate metal ions to promote aptamer^
thrombin interactions [16,17]. A ¢brinogen assay was used with the
aptamer (or scrambled aptamer) at 20 nM and thrombin at 7 nM
(pre-incubated for 60 s), and bovine ¢brinogen (2.0 mg/ml) was
then added to the bu¡er/aptamer^thrombin solution. Of the bu¡ers
examined, we found that HNPK (20 mM HEPES, 145 mM NaCl,
5 mM KCl, 0.1% polyethylene glycol 8000, 0.02% NaN3 at pH 7.4)
promoted the best activity with the aptamer (data not included).
Inhibition assays were performed using HNPK/BSA (bovine serum
albumin)-coated microtiter plates as described previously [29^32]. In
the absence of glycosaminoglycan, 1 nM thrombin was incubated with
500 nM serpin, and either 1 WM aptamer or scrambled aptamer. In
the presence of ¢xed amounts of glycosaminoglycan, 1 nM thrombin
(K- or QT-) was incubated with 10 nM serpin, various amounts or
aptamer or scrambled aptamer (from 0.0001 to 1 WM), and glycos-
aminoglycan (10 Wg/ml heparin for HCII; 1 or 5 Wg/ml heparin for
ATIII; or 20 Wg/ml dermatan sulfate for HCII). Assays with HCII^ or
AT^thrombin in the presence of varying amounts of heparin (0.10^
100 Wg/ml for AT and 1^1000 Wg/ml for HCII) were performed with
10 nM serpin, 1 nM thrombin, and 5 nM aptamer. Inhibition reac-
tions and residual thrombin activity were determined using both con-
tinuous and discontinuous assays, and rate constants were calculated
as described previously [29^32].
2.3. Molecular modeling
The HCII^thrombin complex was constructed essentially as de-
scribed previously using the Homology module of the Insight II mo-
lecular modeling package (Version 2.3.0, BIOSYM TECHNOLO-
GIES, Inc., San Diego, CA, USA) [33,34]. The X-ray crystal
structure of K-thrombin complexed with the thrombin aptamer and
D-Phe-Pro-Arg-chloromethyl ketone ([35]; Brookhaven entry 1HAO)
was obtained from the Brookhaven Protein Data Bank. The coordi-
nates of the backbone atoms in the thrombin molecule were aligned in
Insight II. Connolly solvent accessible surfaces for HCII, thrombin,
aptamer, and D-Phe-Pro-Arg-chloromethyl ketone were created in In-
sight II using a probe radius of 1.4 Aî .
3. Results
3.1. In£uence of thrombin aptamer on HCII/AT^thrombin
inhibition in the absence of glycosaminoglycans
Without glycosaminoglycan present, the aptamer slightly
reduces the thrombin inhibition rate by HCII to
1.52 þ 0.07U104 M31 min31, compared to 2.51 þ 0.01U104
M31 min31 with the scrambled aptamer and 2.60 þ 0.07U
104 M31 min31 in the absence of aptamer. The interaction
of the aptamer with thrombin showed no e¡ect in AT inhibi-
tion of thrombin activity with an inhibition rate in the pres-
ence of aptamer of 2.76 þ 0.38U105 M31min31, in compari-
son to 2.62 þ 0.33U105 M31 min31 with the scrambled
aptamer and 2.48 þ 0.22U105 M31 min31 in the absence of
aptamer.
3.2. In£uence of thrombin aptamer on HCII/AT^thrombin
inhibition in the presence of glycosaminoglycans
In contrast to the data above, HCII inhibition in the pres-
ence of heparin and dermatan sulfate was dramatically altered
by aptamer^thrombin interactions. In the presence of 1 WM
aptamer, there was a greater than 96% attenuation of the
glycosaminoglycan-enhanced inhibition reaction (Table 1). A
signi¢cant loss of thrombin inhibitory activity by HCII was
found when using various aptamer amounts from 0.001 to 0.1
WM in the presence of either heparin and dermatan sulfate,
with an aptamer I50% of V5 nM for both glycosaminoglycans
(Fig. 1). There was an e¡ect of the scrambled aptamer se-
quence in the presence of dermatan sulfate but not with hep-
arin, possibly attributed to dermatan sulfate being more de-
pendent on thrombin exosite-I during inhibition by HCII
(Fig. 1). The thrombin aptamer substantially reduced the
rate of thrombin inhibition over a wide range of heparin con-
centrations with a maximal inhibition of 12U107 M31 min31
in the presence of aptamer compared to 41U107 M31 min31
in its absence (Fig. 2). These results suggest that thrombin
aptamer^thrombin interactions alter the HCII^glycosamino-
glycan inhibition reaction for thrombin.
The thrombin aptamer only had a minor e¡ect on the AT^
heparin inhibition of thrombin, and there was no e¡ect of the
scrambled aptamer to alter the inhibition reaction (Table 1
and Fig. 1). The small in£uence for the aptamer on AT^hep-
arin was mimicked when QT-thrombin, a derivative lacking
anion-binding exosite-I, was used in place of K-thrombin (Ta-
ble 1). Varying the concentration of heparin with a ¢xed
amount of thrombin aptamer showed an V1.4-fold loss of
activity for AT^heparin (Fig. 2). These results indicate that
Table 1
In£uence of thrombin aptamer on serpin^glycosaminoglycan thrombin inhibitiona
Serpin^protease Conditions k2 (M31 min31)U107 Ratio (serpin^aptamer/serpin alone)
HCII/K-thrombin Heparin
HCII alone 19.6 þ 3.5 1.0
HCII+aptamer 6 0.10 6 0.001
HCII+scrambled 20.9 1.1
HCII^K-thrombin Dermatan sulfate
HCII alone 13.8 þ 1.0 1.0
HCII+aptamer 0.37 þ .31 0.03
HCII+scrambled 7.13 þ 1.6 0.52
AT^K-thrombin Heparin
AT alone 133 þ 15 1.0
AT+aptamer 82.0 þ 5.6 0.62
AT+scrambled 133 þ 13 1.0
AT^QT -thrombin Heparin
AT Alone 71.5 þ 3.8 1.0
AT+Aptamer 58.1 þ 4.2 0.81
AT+Scrambled 71.9 þ 1.9 1.0
aSerpin/thrombin assay was performed at room temperature in HNPK with 10 nM serpin, 1 nM (K- or QT)-thrombin, 1 WM aptamer or 1WM
scrambled sequence and 10 Wg/ml (or 667 nM) heparin with HCII, 5 Wg/ml (or 334 nM) heparin with ATIII, and 20 Wg/ml (or 444 nM) derma-
tan sulfate with HCII. The assays were done three separate times in triplicate (except for the scrambled aptamer with HCII^heparin, which
was done two separate times).
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the thrombin aptamer has little in£uence on AT^heparin
thrombin inhibition, which is consistent with a less important
role for exosite-I during the AT inhibition reaction.
4. Discussion
The goals of anticoagulant therapy in cardiovascular dis-
ease are to inhibit ¢brin deposition and platelet aggregation,
which prevent ongoing ischemic events and to prolong the
patients life [36^39]. There are many established antithrom-
botic agents like aspirin, coumarin and unfractionated hepa-
rin. While these agents have well-established biological actions
there are some limitations to their e¡ectiveness; thus, a search
for new and novel antithrombotics has been underway for the
past 15 years [36^39]. The thrombin aptamer described by
Bock and co-workers [16^18] is a potent antithrombotic,
both in vitro and in vivo, and it possesses some potential
for clinical application [24]. Aptamers have now been pre-
pared to both exosite-I [16^18] and exosite-II of thrombin
[19]. The speci¢city of thrombin aptamers provides a unique
biomedical/biochemical tool to probe thrombin’s interactions
with macromolecular substrates.
We evaluated the e¡ect of the exosite-I-speci¢c thrombin
aptamer on serpin-catalyzed thrombin inhibition reactions,
comparing HCII to AT. The aptamer had virtually no in£u-
ence on thrombin inhibition by AT in either the absence or
presence of glycosaminoglycans. The results veri¢ed that AT
has no major interaction with exosite-I of thrombin with or
without heparin ([30,40] and references cited therein). The
inhibitory activity of HCII in the absence of glycosamino-
glycan was slightly a¡ected by the thrombin aptamer, with
the k2 value decreased Vtwo-fold, and is comparable to de-
creases with QT-thrombin and the dysthrombin variant Quick I
(Arg67CCys) with HCII [27,41]. These results are consistent
with the thrombin aptamer decreasing the positive electro-
static potential of exosite-I, which could slightly reduce the
association rate constant between HCII and thrombin.
A large decrease in the rate of thrombin inhibition was
found for HCII^glycosaminoglycans in the presence of the
thrombin aptamer. These results agree with the evidence
that exosite-I is critical for HCII inhibition especially cata-
lyzed by glycosaminoglycans ([30] and references cited there-
in). HCII contains an N-terminal acidic region (residues 56^
75) similar in sequence to the C-terminal tail of hirudin [42].
The HCII acidic domain is required for inhibition of throm-
bin in the presence of glycosaminoglycan by interacting with
thrombin’s exosite-I, and it is also postulated to bind to the
glycosaminoglycan-binding site in the absence of glycosami-
noglycans [32,43,44]. We recently found that Arg67 and Arg73
in exosite-I of thrombin have a major role in complex forma-
tion with HCII in the presence of glycosaminoglycan (Fig. 3,
Fig. 1. HCII and AT inhibition of thrombin in the presence of
thrombin aptamer and glycosaminoglycans. Reaction conditions
were 10 nM serpin, 1 nM thrombin, 1 Wg/ml (or 67 nM) heparin
with AT, 10 Wg/ml (or 667 nM) heparin with HCII, or 20 Wg/ml (or
444 nM) dermatan sulfate with HCII, and 0.001^1 WM aptamer (F)
or 1 WM scrambled aptamer (R). Top is HCII/heparin; middle is
HCII/dermatan sulfate and bottom is AT/heparin.
Fig. 2. HCII and AT inhibition of thrombin in the presence of
thrombin aptamer and heparin. Final concentrations were 10 nM
serpin, 1 nM thrombin, without (b) or with 5 nM aptamer (F), and
heparin from 0.1 to 1000 Wg/ml (or 6.7^66 667 nM). Top is HCII;
bottom is AT.
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top panel) [31]. In contrast, there was only a minimal e¡ect of
the other basic residues in exosite-I on HCII^glycosaminogly-
can thrombin inhibition (Fig. 3, top panel) [31]. Interestingly,
the thrombin aptamer interacts with both Arg67 and Arg73 of
thrombin (Fig. 3, middle and bottom panels). Consistent with
our past mutagenesis study, aptamer binding to Arg67 and
Arg73 would greatly contribute to the loss of inhibitory activ-
ity by HCII in the presence of glycosaminoglycans (Fig. 3,
bottom panel). We conclude that the interaction of the com-
plementary electrostatic ¢eld of thrombin exosite-I for the
HCII acidic domain would be greatly diminished following
thrombin aptamer binding to thrombin.
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